CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.
about
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in ChinaResults from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancerDetermination of chidamide in rat plasma by LC-MS and its application to pharmacokinetics study.Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.Histone Modification Is Involved in Okadaic Acid (OA) Induced DNA Damage Response and G2-M Transition Arrest in Maize.Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 DegradationSynergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signalingTargeting the histone orthography of cancer: drugs for writers, erasers and readers.The Role of HDACs as Leukemia Therapy Targets using HDI.Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.Reactive oxygen species, glutathione, and thioredoxin influence suberoyl bishydroxamic acid-induced apoptosis in A549 lung cancer cells.Chidamide in the treatment of peripheral T-cell lymphomaCombination of betulinic acid and chidamide synergistically inhibits Epstein-Barr virus replication through over-generation of reactive oxygen species.Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.Combination of betulinic acid and chidamide inhibits acute myeloid leukemia by suppression of the HIF1α pathway and generation of reactive oxygen species.Chidamide shows synergistic cytotoxicity with cytarabine via inducing G0/G1 arrest and apoptosis in myelodysplastic syndromes.Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells.The plant alkaloid tetrandrine inhibits metastasis via autophagy-dependent Wnt/β-catenin and metastatic tumor antigen 1 signaling in human liver cancer cells.Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone diseaseEffects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines
P2860
Q28070073-6E3EA29A-5533-427D-AEF9-561969A70444Q33423854-C6BC1895-65E4-47D9-B9CB-DF2CDA2B8D03Q33435461-54579E12-28DE-4377-AD49-0514FB1BAD3EQ34822075-B5D0B0B7-7030-4E3C-A8DA-3FC0BC6F73D4Q34935239-80D8C44D-771A-41B7-B233-330D99B8BDF0Q35484306-51BEF85E-01DB-4AD6-9C7A-5F961607A195Q36022454-B9F3CC3C-5652-4C55-AE79-7F6ED52B684DQ36201181-313BAA54-5D7C-41F7-BE80-D2C399C863A4Q37040669-0EAD7C91-1166-44C1-891C-31F89BE942ABQ37144116-5B3799EB-BE18-4326-8558-872E324FA636Q38231327-F79846F6-96BC-4F8E-936C-3C727B53A6C4Q38341929-1AEE347A-D0B9-4AAE-AD9F-E0777ACB3171Q38595978-B9D585B8-9D27-48B9-9393-EFB26A37AE2DQ38703315-93443065-87B3-46C3-A111-08FB27DF3C1BQ38765451-9D8485B5-4E04-483C-A464-4E013169E0CFQ38770098-EACA00CE-4044-4282-BFEC-EA89872680C1Q38925745-82D2F188-9125-409A-BBAC-73186DCE5856Q39110404-9E5DB494-D3A8-43EF-9913-89CE338719FFQ41924415-338DE1B3-0276-4B20-A21F-1FD92A996E85Q43269281-637E0BCC-726C-442F-BA93-106F86C329EEQ45873027-E570648E-A47E-46FF-B82C-1FDD3465ABD2Q46246664-DEA00BF2-6409-4910-92F8-73D328C9F0F6Q47220700-A05ADEAB-52B7-47ED-8A6D-F0F91493623FQ48533275-CEFB2E19-E2F4-4DE2-A1BF-7187C929C51BQ49243526-7C7A1FC7-2550-43D0-A0DD-9861BCCC4392Q52764678-F2BAC904-28E5-4D51-AABE-EAA1EA94A3C7Q57172251-03682EF2-3CB3-4B89-8EE2-0190D376477FQ58776042-1F574B29-8701-425F-84F4-DDE1C703F798
P2860
CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
CS055 (Chidamide/HBI-8000), a ...... tion in human leukaemia cells.
@en
CS055 (Chidamide/HBI-8000), a ...... tion in human leukaemia cells.
@nl
type
label
CS055 (Chidamide/HBI-8000), a ...... tion in human leukaemia cells.
@en
CS055 (Chidamide/HBI-8000), a ...... tion in human leukaemia cells.
@nl
prefLabel
CS055 (Chidamide/HBI-8000), a ...... tion in human leukaemia cells.
@en
CS055 (Chidamide/HBI-8000), a ...... tion in human leukaemia cells.
@nl
P2093
P2860
P356
P1433
P1476
CS055 (Chidamide/HBI-8000), a ...... tion in human leukaemia cells.
@en
P2093
P2860
P304
P356
10.1042/BJ20111685
P407
P577
2012-05-01T00:00:00Z